North America GLP-1 Agonists Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 6.94 Billion |
| Market Size (2029) | USD 6.68 Billion |
| CAGR (2024 - 2029) | -0.76 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
North America GLP-1 Agonists Market Analysis
The North America Glucagon-like Peptide-1 Agonists Market size is estimated at USD 6.94 billion in 2024, and is expected to decline to USD 6.68 billion by 2029.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition.
The North American region had witnessed an alarming increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates by monitoring their blood glucose levels.
The Centers for Disease Control and Prevention National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.
Owing to the rising prevalence and factors above, the growth of the studied market is anticipated over the forecast period.
North America GLP-1 Agonists Market Trends
Liraglutide Segment holds the highest market share in the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year
Liraglutide drug holds the highest market share of about 42.6% in the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year.
GLP1RAs are available internationally and are recommended for use when treatment escalation for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Liraglutide, sold under Victoza, is an anti-diabetic medication for treating type 2 diabetes, obesity, and chronic weight management.
Liraglutide controls high blood sugar levels alone or in combination with other medications. It is prescribed to people with type 2 diabetes. Liraglutide is also used to reduce the risk of heart attack, stroke, or death in people with type 2 diabetes and heart disease. It works by increasing insulin release in response to high blood sugar levels after a meal and decreasing the amount of sugar produced by the liver. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
To help make the therapy cost more manageable, the Victoza Instant Savings Card Program allows the patient to print the savings card for instant use. With this card, the patient pays not more than USD 25 per Victoza prescription fill, valid for two years. It is equivalent to 24 prescription refills. However, due to the increased efficacy of the exenatide and semaglutide and the risks associated with Liraglutide causing dose-dependent and treatment-duration-dependent thyroid C-cell tumors, it will face tough competition leading to a decline in sales during the forecast period.
United States held the highest market share in the North America Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year
United States held the highest market share of about 95% in the North American Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year.
In addition to lowering blood glucose levels to help treat type 2 diabetes, GLP-1 agonists are also used in weight loss and other metabolic health benefits. GLP-1 RAs can be taken alone or in combination with other treatments for type 2 diabetes to improve blood glucose management, i.e., time in range. In addition to lowering blood glucose, they benefit heart health by reducing the risk of heart attack, stroke, and heart-related death. It is important because people with type 2 diabetes are at substantially higher risk of heart disease than those without diabetes.
In August 2022, Novo Nordisk announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analog, cagrilintide. The trial investigated the efficacy and safety of a fixed dose combination of CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) compared to the individual components, all administered once weekly, in 92 people with type 2 diabetes and overweight.
Owing to the rising prevalence and factors above, the growth of the studied market is anticipated over the forecast period.
North America GLP-1 Agonists Industry Overview
The North America Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, etc.
North America GLP-1 Agonists Market Leaders
-
Astrazeneca
-
Sanofi
-
Eli Lilly and Company
-
Pfizer Inc.
-
Novo Nordisk A/S
*Disclaimer: Major Players sorted in no particular order
North America GLP-1 Agonists Market News
- January 2023: The U.S. Food and Drug Administration approved semaglutide (Wegovy- Novo Nordisk) for treating obesity in pediatric patients 12 years and older. The approval was granted following the results of a phase 3a study published in the New England Journal of Medicine. Participants in the trial were given semaglutide or a placebo for 68 weeks alongside lifestyle intervention. Safety, efficacy, and tolerability were compared between these 2 groups.
- May 2022: The U.S. Food and Drug Administration approved Eli Lilly and Company's Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
North America GLP-1 Agonists Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 Drugs
- 5.1.1 Dulaglutide
- 5.1.1.1 Trulicity
- 5.1.2 Exenatide
- 5.1.2.1 Byetta
- 5.1.2.2 Bydureon
- 5.1.3 Liraglutide
- 5.1.3.1 Victoza
- 5.1.4 Lixisenatide
- 5.1.4.1 Lyxumia
- 5.1.5 Semaglutide
- 5.1.5.1 Ozempic
-
5.2 Geography
- 5.2.1 United States
- 5.2.2 Canada
- 5.2.3 Rest of North America
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. Competitive Landscape
-
7.1 Company Profiles
- 7.1.1 Novo Nordisk
- 7.1.2 AstraZeneca
- 7.1.3 Eli Lilly and Company
- 7.1.4 Sanofi
- 7.1.5 Pfizer
- *List Not Exhaustive
-
7.2 Company Share Analysis
- 7.2.1 Novo Nordisk
- 7.2.2 AstraZeneca
- 7.2.3 Eli Lilly and Company
- 7.2.4 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNorth America GLP-1 Agonists Industry Segmentation
GLP-1 receptor agonists are a non-insulin medication combined with diet and exercise to help treat type 2 diabetes. The North American Glucagon-like Peptide-1 (GLP-1) Agonists Market is segmented into drugs and geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Drugs | Dulaglutide | Trulicity |
| Drugs | Exenatide | Byetta |
| Bydureon | ||
| Drugs | Liraglutide | Victoza |
| Drugs | Lixisenatide | Lyxumia |
| Drugs | Semaglutide | Ozempic |
| Geography | United States | |
| Canada | ||
| Rest of North America |
North America GLP-1 Agonists Market Research FAQs
What is the current North America Glucagon-like Peptide-1 Agonists Market size?
In 2024, the North America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 6.94 billion.
Who are the key players in North America Glucagon-like Peptide-1 Agonists Market?
Astrazeneca, Sanofi, Eli Lilly and Company, Pfizer Inc. and Novo Nordisk A/S are the major companies operating in the North America Glucagon-like Peptide-1 Agonists Market.
What years does this North America Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?
In 2023, the North America Glucagon-like Peptide-1 Agonists Market size was estimated at USD 6.99 billion. The report covers the North America Glucagon-like Peptide-1 Agonists Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America GLP-1 Agonists Industry Report
The North America GLP-1 Agonists market is segmented into various drugs, including Dulaglutide (Trulicity), Exenatide (Byetta and Bydureon), Liraglutide (Victoza), Lixisenatide (Lyxumia), and Semaglutide (Ozempic). The market is further divided by geography, covering the United States, Canada, and the rest of North America. This comprehensive market report provides valuable insights into the market size, market share, and market growth of these drugs within the region.
The industry analysis offers a detailed overview of the industry outlook and industry trends, highlighting significant market data and industry statistics. The report also includes market research and industry research to understand the market segmentation and market value.
With a focus on market forecast and market predictions, the report reviews the market outlook and market review to identify the market leaders and provide an in-depth industry overview. The industry reports and market report are essential for understanding the market trends and growth rate within the North America GLP-1 Agonists market.
This report example and report PDF serve as a valuable resource for research companies and industry professionals. The market analysis and industry information contained within the report are crucial for understanding the market segmentation and market value.
Overall, the report highlights the market growth and industry sales, providing a comprehensive market overview and industry outlook for the North America GLP-1 Agonists market. The report's detailed analysis and market segmentation offer valuable insights into the market trends and industry statistics, making it an essential tool for market leaders and research companies.
